Lauren Fields, APRN
Adult Health · Overland Park, KSNPI 1487195517
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 713 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $3,245 and has fallen 54.2% since, to $1,485 in 2025. Among adult health clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 713 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Novo Nordisk$2K
- Boehringer Ingelheim$879
- Abbott$855
- AbbVie$633
- Bayer$624
- plus $6K from 37 others
What the payments were for
- Food & beverage$12,276100%
- Education$530%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$12,329 in reported general payments places this provider in the 95th percentile of 155 adult health providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 313 | $551,827 |
| MounjaroTirzepatide | 189 | $299,099 |
| JardianceEmpagliflozin | 170 | $203,942 |
| Tresiba Flextouch U-200Insulin Degludec | 90 | $142,721 |
| TrulicityDulaglutide | 78 | $124,381 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 51 | $92,994 |
| FarxigaDapagliflozin Propanediol | 81 | $87,281 |
| Tresiba Flextouch U-100Insulin Degludec | 118 | $75,452 |
| JanuviaSitagliptin Phosphate | 62 | $71,337 |
| GlyxambiEmpagliflozin/Linagliptin | 37 | $41,692 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $40,755 |
| Novolog FlexpenInsulin Aspart | 87 | $39,528 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $36,890 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 47 | $33,852 |
| RybelsusSemaglutide | 21 | $30,851 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,790 | $589,250355 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Insulin Lispro | $1,964 | $441,862294 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta, Synjardy Xr | $879 | $289,650243 claims |
| AstraZenecaFarxiga | $575 | $87,28181 claims |
| MerckJanuvia | $207 | $71,33762 claims |
| BayerKerendia | $624 | $16,21614 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $330 | $2,469281 claims |
| Sanofi-aventis U.S. LLCLantus | $340 | $2,25512 claims |
| AbbVieSynthroid | $633 | $1,99228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 155 adult health providers in Kansas.
Other adult health in Overland Park
- Tina LegaultOverland Park$12K
- Monica PfeifferOverland Park$7K
- Amy RiederOverland Park$6K
- Paige BudzinskiOverland Park$4K
- Mary MartinOverland Park$2K
- Carla ShepardOverland Park$2K
- Jill SoenenOverland Park$1K
- Carrie EnglertOverland Park$1K
- Debra MorrisOverland Park$1K
- Christina SchmidtOverland Park$968
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.